{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:48:40Z","timestamp":1767901720620,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40262-025-01577-2","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:29:04Z","timestamp":1762176544000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low Target Attainment of Intravenous Cefuroxime in Critically Ill Term Neonates and Children: A Pooled Population Pharmacokinetics Study"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-0749","authenticated-orcid":false,"given":"Stef","family":"Schouwenburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-0358","authenticated-orcid":false,"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-2131","authenticated-orcid":false,"given":"Roelie M. W\u00f6sten-van","family":"Asperen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-3244","authenticated-orcid":false,"given":"Stan J. F.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-0647","authenticated-orcid":false,"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-581X","authenticated-orcid":false,"given":"Matthijs","family":"de Hoog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-3643","authenticated-orcid":false,"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-6376","authenticated-orcid":false,"given":"Alan","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5197-2656","authenticated-orcid":false,"given":"Enno D.","family":"Wildschut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"4","key":"1577_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1128\/AAC.28.4.504","volume":"28","author":"CM Ginsburg","year":"1985","unstructured":"Ginsburg CM, McCracken GH Jr, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother. 1985;28(4):504\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1577_CR2","doi-asserted-by":"publisher","first-page":"8826","DOI":"10.1038\/s41598-020-65671-0","volume":"10","author":"H Renk","year":"2020","unstructured":"Renk H, Sarmisak E, Spott C, Kumpf M, Hofbeck M, H\u00f6lzl F. Antibiotic stewardship in the PICU: impact of ward rounds led by paediatric infectious diseases specialists on antibiotic consumption. Sci Rep. 2020;10(1):8826.","journal-title":"Sci Rep"},{"issue":"6","key":"1577_CR3","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1097\/PCC.0b013e31828a846d","volume":"14","author":"E Blinova","year":"2013","unstructured":"Blinova E, Lau E, Bitnun A, Cox P, Schwartz S, Atenafu E, et al. Point prevalence survey of antimicrobial utilization in the cardiac and pediatric critical care unit. Pediatr Crit Care Med. 2013;14(6):e280\u20138.","journal-title":"Pediatr Crit Care Med"},{"issue":"2","key":"1577_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","volume":"59","author":"SJF Hartman","year":"2020","unstructured":"Hartman SJF, Br\u00fcggemann RJ, Orri\u00ebns L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature. Clin Pharmacokinet. 2020;59(2):173\u2013205.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1577_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","volume":"34","author":"N Thakkar","year":"2017","unstructured":"Thakkar N, Salerno S, Hornik CP, Gonzalez D. Clinical pharmacology studies in critically ill children. Pharm Res. 2017;34(1):7\u201324.","journal-title":"Pharm Res"},{"issue":"2","key":"1577_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","volume":"62","author":"D Morales Castro","year":"2023","unstructured":"Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62(2):209\u201320.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1577_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17425255.2021.1879049","volume":"17","author":"A Abdulla","year":"2021","unstructured":"Abdulla A, Ewoldt TMJ, Purmer IM, Muller AE, Gommers D, Endeman H, et al. A narrative review of predictors for \u03b2-lactam antibiotic exposure during empirical treatment in critically ill patients. Expert Opin Drug Metab Toxicol. 2021;17(4):359\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"1577_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1128\/AAC.9.5.741","volume":"9","author":"RD Foord","year":"1976","unstructured":"Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother. 1976;9(5):741\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1577_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-019-04205-x","volume":"34","author":"T Van Der Heggen","year":"2019","unstructured":"Van Der Heggen T, Dhont E, Peperstraete H, Delanghe JR, Vande Walle J, De Paepe P, et al. Augmented renal clearance: a common condition in critically ill children. Pediatr Nephrol. 2019;34(6):1099\u2013106.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"1577_CR10","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","volume":"21","author":"SL Weiss","year":"2020","unstructured":"Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med. 2020;21(2):e52\u2013106.","journal-title":"Pediatr Crit Care Med"},{"key":"1577_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.777854","volume":"10","author":"R Morales Junior","year":"2022","unstructured":"Morales Junior R, Pereira GO, Tiguman GMB, Juodinis VD, Telles JP, de Souza DC, et al. Beta-lactams therapeutic monitoring in septic children-What target are we aiming for? A scoping review. Front Pediatr. 2022;10:777854.","journal-title":"Front Pediatr"},{"issue":"6","key":"1577_CR12","volume":"3","author":"EF Barreto","year":"2021","unstructured":"Barreto EF, Webb AJ, Pais GM, Rule AD, Jannetto PJ, Scheetz MH. Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling? Crit Care Explor. 2021;3(6):e0446.","journal-title":"Crit Care Explor"},{"issue":"10","key":"1577_CR13","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/jac\/dku195","volume":"69","author":"M Carlier","year":"2014","unstructured":"Carlier M, No\u00eb M, Roberts JA, Stove V, Verstraete AG, Lipman J, et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. J Antimicrob Chemother. 2014;69(10):2797\u2013803.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1577_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/bpb.31.316","volume":"31","author":"HJ Olgu\u00edn","year":"2008","unstructured":"Olgu\u00edn HJ, Asseff IL, Vieyra AC, P\u00e9rez AG, Salda\u00f1a NG, Quesada AC, et al. Effect of severity disease on the pharmacokinetics of cefuroxime in children with multiple organ system failure. Biol Pharm Bull. 2008;31(2):316\u201320.","journal-title":"Biol Pharm Bull"},{"key":"1577_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.750080","author":"S Schouwenburg","year":"2021","unstructured":"Schouwenburg S, Wildschut ED, de Hoog M, Koch BCP, Abdulla A. The pharmacokinetics of beta-lactam antibiotics using scavenged samples in pediatric intensive care patients: the EXPAT kids study protocol. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.750080.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1577_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23100","volume":"34","author":"JJ van Raaij","year":"2020","unstructured":"van Raaij JJ, Mabelis NJD, Shudofsky KN, Meenks SD, le Noble J, Janssen PKC. Quantification of total and unbound cefuroxime in plasma by ultra-performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure. J Clin Lab Anal. 2020;34(3):e23100.","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"1577_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1128\/AAC.37.6.1343","volume":"37","author":"JM Benson","year":"1993","unstructured":"Benson JM, Boudinot FD, Pennell AT, Cunningham FE, DiPiro JT. In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera. Antimicrob Agents Chemother. 1993;37(6):1343\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1577_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11(2):371\u201380.","journal-title":"AAPS J"},{"issue":"4","key":"1577_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/ki.2012.169","volume":"82","author":"GJ Schwartz","year":"2012","unstructured":"Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et al. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int. 2012;82(4):445\u201353.","journal-title":"Kidney Int"},{"issue":"5","key":"1577_CR20","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00467-023-06221-4","volume":"39","author":"E Dhont","year":"2024","unstructured":"Dhont E, Van Der Heggen T, Snauwaert E, Willems J, Croubels S, Delanghe J, et al. Predictors of augmented renal clearance based on iohexol plasma clearance in critically ill children. Pediatr Nephrol. 2024;39(5):1607\u201316.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"1577_CR21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187\u201397.","journal-title":"Pharm Res"},{"issue":"6","key":"1577_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"AG Dosne","year":"2017","unstructured":"Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44(6):509\u201320.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1577_CR23","unstructured":"EUCAST. Clinical breakpoints and dosing of antibiotics: EUCAST: 2021. Available from: http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"issue":"7","key":"1577_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0002-9378(16)32526-1","volume":"142","author":"A Philipson","year":"1982","unstructured":"Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol. 1982;142(7):823\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"1577_CR25","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1128\/AAC.22.6.990","volume":"22","author":"ML del Rio","year":"1982","unstructured":"del Rio ML, Chrane DF, Shelton S, McCracken GH Jr., Nelson JD. Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis. Antimicrob Agents Chemother. 1982;22(6):990\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1577_CR26","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1111\/bcp.13632","volume":"84","author":"R Gertler","year":"2018","unstructured":"Gertler R, Gruber M, Wiesner G, Grassin-Delyle S, Urien S, Tassani-Prell P, et al. Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery. Br J Clin Pharmacol. 2018;84(9):2020\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1577_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107267","volume":"64","author":"R Morales Jr.","year":"2024","unstructured":"Morales R Jr., Mizuno T, Paice KM, Hambrick HR, Punt N, Tang Girdwood S. Impact of fluid balance on beta-lactam antibiotics target attainment: insights from a simulation-based meropenem study. Int J Antimicrob Agents. 2024;64(3):107267.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1577_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","volume":"35","author":"E Dhont","year":"2020","unstructured":"Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol. 2020;35(1):25\u201339.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1577_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00431-023-05272-x","volume":"183","author":"WX Xu","year":"2024","unstructured":"Xu WX, Qu Q, Teng XQ, Zhuang HH, Liu SF, Wang Y, et al. Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: a review of literature. Eur J Pediatr. 2024;183(1):51\u201360.","journal-title":"Eur J Pediatr"},{"issue":"10","key":"1577_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/phar.2617","volume":"41","author":"DH Rhoney","year":"2021","unstructured":"Rhoney DH, Metzger SA, Nelson NR. Scoping review of augmented renal clearance in critically ill pediatric patients. Pharmacotherapy. 2021;41(10):851\u201363.","journal-title":"Pharmacotherapy"},{"key":"1577_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241258049","volume":"15","author":"C Jiang","year":"2024","unstructured":"Jiang C, Zheng X, Li P, Qian J, Li Q. A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime. Ther Adv Drug Saf. 2024;15:20420986241258049.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"1577_CR32","first-page":"32","volume":"75","author":"DG van Dam","year":"2017","unstructured":"van Dam DG, Burgers DM, Foudraine N, Janssen PK, Neef C, le Noble JL. Treatment of cefuroxime-induced neurotoxicity with continuous venovenous haemofiltration. Neth J Med. 2017;75(1):32\u20134.","journal-title":"Neth J Med"},{"issue":"6","key":"1577_CR33","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1212\/WNL.50.6.1873","volume":"50","author":"YO Herishanu","year":"1998","unstructured":"Herishanu YO, Zlotnik M, Mostoslavsky M, Podgaietski M, Frisher S, Wirguin I. Cefuroxime-induced encephalopathy. Neurology. 1998;50(6):1873\u20135.","journal-title":"Neurology"},{"issue":"8","key":"1577_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","volume":"332","author":"JM Dulhunty","year":"2024","unstructured":"Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al. Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial. JAMA. 2024;332(8):629\u201337.","journal-title":"JAMA"},{"issue":"3","key":"1577_CR35","first-page":"214","volume":"27","author":"TA Imburgia","year":"2022","unstructured":"Imburgia TA, Kussin ML. A review of extended and continuous infusion beta-lactams in pediatric patients. J Pediatr Pharmacol Ther. 2022;27(3):214\u201327.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"1577_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","volume":"52","author":"JA Roberts","year":"2013","unstructured":"Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1\u20138.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01577-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:31:03Z","timestamp":1767886263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01577-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01577-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the MRace grant of the Erasmus University Medical Centre, Rotterdam, the Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Birgit C.P. Koch and Saskia N. de Wildt are Editorial Board members of\n                      Clinical Pharmacokinetics\n                      . Birgit C.P. Koch and Saskia N. de Wildt were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Stef Schouwenburg, Tim Preijers, Alan Abdulla, Roelie M. W\u00f6sten-van Asperen, Stan J.F. Hartman, Saskia N. de Wildt, Matthijs de Hoog, and Enno D. Wildschut have no conflicts of interest to declare concerning this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data and material are accessible upon reasonable request by contacting the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The EXPAT Kids study was approved by the Erasmus MC Medical Ethical Committee (NL76194.078.21) (NL9326).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors made substantial contributions to the conception and design of the PK trial, interpretation of data, and funding acquisition. Stef Schouwenburg and Tim Preijers were responsible for data analysis and directly accessed and verified the underlying data presented here. Stef Schouwenburg drafted the manuscript. All authors provided a critical revision for important intellectual content. All authors approved the final version to be published and agreed to be accountable for all aspects of the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Written, informed consent was obtained from all participants. All participants consented to publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants consented to publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The model codes that support the findings of this study are accessible upon reasonable request by contacting the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}